Skip to content
ClinCalc Pro
Menu
Anti-Staphylococcal Penicillin

Flucloxacillin (Paediatric)

Brand names: Floxapen

Flucloxacillin is a narrow-spectrum penicillinase-resistant penicillin used in children for staphylococcal infections such as skin and soft tissue infections, bone and joint infection and infective endocarditis.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It inhibits bacterial cell wall synthesis by binding penicillin-binding proteins and is stable to staphylococcal beta-lactamase, retaining activity against most Staphylococcus aureus.

Prescribing in practice

  • It is contraindicated in penicillin allergy, and rare cholestatic hepatitis and jaundice can occur up to weeks after stopping, even after a short course.
  • Take oral doses on an empty stomach, ideally before food, as food reduces absorption; high parenteral doses require attention to renal function and electrolytes.
  • Dose by body weight using a children's formulary, with higher doses for deep-seated infections such as osteomyelitis.

Monitoring

On prolonged or high-dose courses monitor liver and renal function and observe for signs of hypersensitivity.

Counselling the patient

  • Give doses about an hour before food and complete the full course.
  • Report any jaundice, pale stools, dark urine, rash or itching, which can appear after treatment ends.
  • Tell the team about any previous reaction to penicillin or other antibiotics.

Evidence & guidelines

Flucloxacillin is the established first-line antistaphylococcal penicillin in UK practice, with MHRA advice highlighting the risk of delayed cholestatic hepatic reactions.

Reference: NICE NG141 Cellulitis; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.